[{"id":"23c9f80e-de2c-4354-8721-e76a55ae570e","acronym":"VICORYX-2","url":"https://clinicaltrials.gov/study/NCT02526316","created_at":"2021-01-18T12:12:53.368Z","updated_at":"2024-07-02T16:37:20.304Z","phase":"Phase 1","brief_title":"Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers","source_id_and_acronym":"NCT02526316 - VICORYX-2","lead_sponsor":"Oryx GmbH \u0026 Co. KG","biomarkers":" CDKN2A • IFNG • CD4","pipe":" | ","alterations":" CDKN2A expression","tags":["CDKN2A • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • VicOryx (P16_37-63)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2017-07-02"}]